MRKR
Marker Therapeutics, Inc.
A Houston-based clinical-stage biotech company developing T cell-based immunotherapies for blood cancers and solid tumors. Its signature Multi-Antigen Recognizing (MAR) T cell therapy grows a patient's own tumor-fighting T cells in the lab without genetic modification, unlike engineered CAR-T treatments. The company's roots trace to research at Baylor College of Medicine, and its name comes from the tumor "markers" (antigens) its T cells are trained to spot. The current public company was formed in 2018 when TapImmune Inc. merged with the privately held Marker Therapeutics and took on its name.
CUSIP: 57055L206HealthcareUS1 holder
Total Value
$19.5K
Total Shares
15.0K
Net Share Change
0
Activity
No changes
Investor
Value
Shares
Weight
Change
